335 related articles for article (PubMed ID: 17412430)
1. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.
Michor F
Trends Pharmacol Sci; 2007 May; 28(5):197-9. PubMed ID: 17412430
[TBL] [Abstract][Full Text] [Related]
2. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
3. Mathematical models of cancer stem cells.
Michor F
J Clin Oncol; 2008 Jun; 26(17):2854-61. PubMed ID: 18539964
[TBL] [Abstract][Full Text] [Related]
4. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Agarwal MB
J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
[No Abstract] [Full Text] [Related]
6. A PDE model for imatinib-treated chronic myelogenous leukemia.
Kim PS; Lee PP; Levy D
Bull Math Biol; 2008 Oct; 70(7):1994-2016. PubMed ID: 18663536
[TBL] [Abstract][Full Text] [Related]
7. Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.
Bright SA; Campiani G; Deininger MW; Lawler M; Williams DC; Zisterer DM
Biochem Pharmacol; 2010 Jul; 80(1):31-8. PubMed ID: 20206141
[TBL] [Abstract][Full Text] [Related]
8. Imatinib: a targeted clinical drug development.
Capdeville R; Silberman S
Semin Hematol; 2003 Apr; 40(2 Suppl 2):15-20. PubMed ID: 12783370
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Carella AM
Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
[No Abstract] [Full Text] [Related]
10. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
[TBL] [Abstract][Full Text] [Related]
11. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.
Agis H; Jaeger E; Doninger B; Sillaber C; Marosi C; Drach J; Schwarzinger I; Valent P; Oehler L
Eur J Clin Invest; 2006 Jun; 36(6):402-8. PubMed ID: 16684124
[TBL] [Abstract][Full Text] [Related]
12. [Clinical studies with imatinib in 2004].
Eckhardt S
Orv Hetil; 2005 May; 146(18 Suppl 1):941-4. PubMed ID: 15921309
[TBL] [Abstract][Full Text] [Related]
13. [Origin of resistance to Imatinib mesylate: lessons learned from this experience].
Roche-Lestienne C; Mahon FX; Preudhomme C
Med Sci (Paris); 2004 Dec; 20(12):1125-30. PubMed ID: 15581468
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate: A designer drug.
Panigrahi I; Naithani R
J Assoc Physicians India; 2006 Mar; 54():203-6. PubMed ID: 16800347
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of chronic myeloid leukaemia.
Michor F; Hughes TP; Iwasa Y; Branford S; Shah NP; Sawyers CL; Nowak MA
Nature; 2005 Jun; 435(7046):1267-70. PubMed ID: 15988530
[TBL] [Abstract][Full Text] [Related]
16. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
17. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging treatment options in chronic myeloid leukemia.
Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
[TBL] [Abstract][Full Text] [Related]
19. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.
Roeder I; Horn M; Glauche I; Hochhaus A; Mueller MC; Loeffler M
Nat Med; 2006 Oct; 12(10):1181-4. PubMed ID: 17013383
[TBL] [Abstract][Full Text] [Related]
20. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
Wodarz D
Med Hypotheses; 2008; 70(1):128-36. PubMed ID: 17566666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
